The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality

Cancer Treatment Reviews
Marios PapadimitriouChristos A Papadimitriou

Abstract

Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers and is characterized by a lack of immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2. TNBC is associated with poor long-term outcomes compared with other breast cancer subtypes. Many of these tumors are also basal-like cancers which are characterized by an aggressive biological behavior with a distant recurrence peak observed early at 3 years following diagnosis. Furthermore, metastatic TNBC bears a dismal prognosis with an average survival of 12 months. Although the prevalence of genetic alterations among women with TNBC differs significantly by ethnicity, race and age, BRCA mutations (including both germline mutations and somatic genetic aberrations) are found in up to 20-25% of unselected patients and especially in those of the basal-like immunophenotype. Therefore, defects in the DNA repair pathway could represent a promising therapeutic target for this subgroup of TNBC patients. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit this deficiency through synthetic lethality and have emerged as promising anticancer therapies, especially in BRCA1 or BRCA2 mutation carriers. Several PARP i...Continue Reading

Citations

Jan 5, 2020·Annals of Surgical Oncology·T J Stankowski-DrenglerH B Neuman
Jan 24, 2019·Journal of Biochemical and Molecular Toxicology·Gamze Guney EskilerBerrin Tunca
Oct 24, 2019·Breast Cancer Research : BCR·Agnieszka MorgenrothFelix M Mottaghy
Oct 24, 2019·Journal of Cellular Physiology·Atefeh Razazan, Javad Behravan
May 28, 2020·International Journal of Molecular Sciences·Janusz BlasiakCezary Chojnacki
Feb 6, 2019·International Journal of Molecular Sciences·Sarah AlexandrouC Elizabeth Caldon
Dec 21, 2020·Pathology, Research and Practice·Niraj KumariNarendra Krishnani
Feb 11, 2021·Cancers·Damiano Cosimo RigiraccioloRosamaria Lappano
Mar 26, 2021·Current Oncology Reports·Elisa AgostinettoEvandro de Azambuja
Jul 29, 2021·Molecular Pharmaceutics·Thomas WilsonJill Bargonetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

© 2022 Meta ULC. All rights reserved